Of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse-type tenosynovial giant cell tumor. Of its phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036) and (2) its Phase 1 study On October 29, 2019, the Company issued a press release announcing updated data for two of its programs, namely (1) updated results Presentations are furnished as Exhibit 99.3 and Exhibit 99.4 to this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the October 28, 2019 in poster sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, MA (the Triple Meeting). Metastatic solid tumors and (2) preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers. Its programs, namely (1) its Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or (the ∼ompany) issued a press release announcing updated data for two of On October 28, 2019, Deciphera Pharmaceuticals, Inc. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodįor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act ofġ933 or Rule 12b-2 of the Securities Exchange Act of 1934. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425) The registrant under any of the following provisions:
(Registrants telephone number, including area code)Ĭheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
(Address of registrants principal executive office) (Exact name of registrant as specified in its charter) Date of Report (Date of earliest event reported): October 28, 2019
0 kommentar(er)
